Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury

Abstract

BackgroundMicroglia/macrophages play a critical role in the inflammatory and immune processes of cerebral ischemia/reperfusion injury. Since microglia/macrophages can reversibly shift their phenotype toward either a “detrimental” or a “restorative” state in the injured central nervous system (CNS), compounds mediate that shift which could inhibit inflammation and restore the ability to alleviate cerebral ischemia/reperfusion injury would have therapeutic potential.MethodsTransient middle cerebral artery occlusion was induced in male C57BL/6 mice. Mice were randomly separated into a sham-operated group, a control group, and a ZSTK474-treated group. We investigated the effect of ZSTK474 by assessing neurological deficits, infarct volume, and histopathological changes. We then determined the potential mechanism by immunofluorescent staining, quantitative real-time polymerase chain reaction (PCR), and Western blot analysis. The Tukey’s test or Mann–Whitney U test was used to compare differences among the groups.ResultsZSTK474 alleviated neurological deficits and reduced infarct volume in the cerebral ischemia/reperfusion injury model. Presumably, ZSTK474 shifted the phenotype of microglia/macrophages to a restorative state, since this treatment decreased the secretion of pro-inflammatory factors and advanced the secretion of anti-inflammatory factors. These neuroprotective properties of ZSTK474 may be mediated by the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin complex 1 (mTORC1) pathway.ConclusionsZSTK474 can mediate a shift in microglia/macrophage phenotype and inhibit the inflammatory response in cerebral ischemia reperfusion injury of mice. These effects appeared to ensue via the PI3K/AKT/mTORC1 pathway. Therefore, ZSTK474 may represent a therapeutic intervention with potential for circumventing the catastrophic aftermath of ischemic stroke.Electronic supplementary materialThe online version of this article (doi:10.1186/s12974-016-0660-1) contains supplementary material, which is available to authorized users.

Delayed decompression exacerbates ischemia-reperfusion injury in cervical compressive myelopathy

“…Studies of other IRI conditions in the CNS suggest a strong correlation between IRI, inflammation, and neurological recovery. For example, PI3K inhibition resulted in altered microglia activation, decreased production of inflammatory cytokines, and improved neurological outcomes in a cerebral IRI model (65). However, it is worth noting that activation of the immune system and astrocytes is not always detrimental and should not be entirely abolished.…”

Microglia Mediated Neuroinflammation: Focus on PI3K Modulation

“…In 2016, Wang and co-workers found that in male C57BL/6 mice ZSTK474, an inhibitor of PI3K had a neuroprotective action because it mitigated cerebral ischemic/reperfusion injury by fostering a beneficial microglial/macrophage phenotype [102].…”

Influenza virus replication in macrophages: balancing protection and pathogenesis

“…Fc receptor-mediated phagocytosis and phagocytic uptake of apoptotic cells is dependent on the activation of phosphoinositide 3-kinase (PI3K) [68]. A PI3K inhibitor decreased expression of CD16 on microglial cells (central nervous system-resident macrophages), suggesting a link between PI3K signalling and Fc receptor expression [69]. Although seasonal H1N1 and H3N2 IAV activate the PI3K signalling pathway in mouse AMs, an H5N1 IAV fails to do the same in infected epithelial cells [70,71].…”